Celgene Co. (NASDAQ:CELG) has earned an average recommendation of “Hold” from the twenty-one analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, nineteen have given a hold rating and one has given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $97.31.
A number of equities analysts have weighed in on CELG shares. Wells Fargo & Co set a $110.00 price target on shares of Celgene and gave the company a “hold” rating in a report on Friday, November 1st. Leerink Swann set a $115.00 target price on Celgene and gave the company a “hold” rating in a report on Friday, November 1st. BidaskClub downgraded Celgene from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 19th. Mizuho restated a “hold” rating and set a $100.00 price target on shares of Celgene in a research note on Sunday, October 20th. Finally, Standpoint Research lowered Celgene from a “buy” rating to a “hold” rating in a research note on Friday, November 1st.
Shares of Celgene stock remained flat at $$108.24 during trading hours on Friday. The company’s stock had a trading volume of 114,302 shares, compared to its average volume of 6,772,216. Celgene has a one year low of $58.59 and a one year high of $110.70. The company’s 50-day moving average is $108.14 and its two-hundred day moving average is $99.01. The company has a debt-to-equity ratio of 1.51, a current ratio of 2.89 and a quick ratio of 2.80. The company has a market capitalization of $77.04 billion, a price-to-earnings ratio of 14.22, a price-to-earnings-growth ratio of 0.51 and a beta of 1.41.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $2.99 EPS for the quarter, beating the Zacks’ consensus estimate of $2.70 by $0.29. Celgene had a net margin of 34.63% and a return on equity of 78.15%. The company had revenue of $4.52 billion during the quarter, compared to the consensus estimate of $4.39 billion. During the same quarter in the prior year, the company posted $2.29 EPS. The company’s quarterly revenue was up 16.1% compared to the same quarter last year. As a group, equities analysts forecast that Celgene will post 10.7 EPS for the current year.
In related news, insider Terrie Curran sold 11,338 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the sale, the insider now directly owns 13,493 shares in the company, valued at approximately $1,325,957.11. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.39% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of CELG. United Bank acquired a new position in shares of Celgene in the 2nd quarter valued at approximately $553,000. KBC Group NV raised its holdings in Celgene by 18.1% in the second quarter. KBC Group NV now owns 446,603 shares of the biopharmaceutical company’s stock valued at $41,284,000 after acquiring an additional 68,517 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in Celgene by 2.7% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,730 shares of the biopharmaceutical company’s stock valued at $899,000 after acquiring an additional 260 shares during the last quarter. Advisor Group Inc. boosted its stake in Celgene by 7.7% during the 2nd quarter. Advisor Group Inc. now owns 52,135 shares of the biopharmaceutical company’s stock valued at $4,817,000 after acquiring an additional 3,705 shares during the last quarter. Finally, Westpac Banking Corp grew its holdings in Celgene by 8.4% during the 2nd quarter. Westpac Banking Corp now owns 75,799 shares of the biopharmaceutical company’s stock worth $7,007,000 after acquiring an additional 5,878 shares in the last quarter. 71.66% of the stock is currently owned by institutional investors and hedge funds.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Further Reading: What is Call Option Volume?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.